

Shahin Sanjar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7880920/publications.pdf>

Version: 2024-02-01

12
papers

40
citations

1936888

4
h-index

1872312

6
g-index

14
all docs

14
docs citations

14
times ranked

46
citing authors

#	ARTICLE	IF	CITATIONS
1	Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies. International Journal of COPD, 2021, Volume 16, 865-875.	0.9	4
2	Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate. International Journal of COPD, 2021, Volume 16, 945-955.	0.9	1
3	Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD. International Journal of COPD, 2021, Volume 16, 1061-1073.	0.9	2
4	Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD. Npj Primary Care Respiratory Medicine, 2021, 31, 43.	1.1	0
5	<p>The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies</p>. International Journal of COPD, 2020, Volume 15, 745-754.	0.9	1
6	The Effect of Metabolic Syndrome Status on Lung Function and Patient-reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 315-326.	0.5	2
7	<p>Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate</p>. International Journal of COPD, 2020, Volume 15, 995-1004.	0.9	5
8	Efficacy and Safety of Nebulized Glycopyrrolate/eFlow® Closed System in Patients with Moderate-to-Very-Severe Chronic Obstructive Pulmonary Disease with Pre-Existing Cardiovascular Risk Factors. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 86-99.	0.5	4
9	Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies. Respiratory Research, 2019, 20, 135.	1.4	8
10	<p>Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of the GEM1 and GEM2 12-week studies</p>. International Journal of COPD, 2019, Volume 14, 461-470.	0.9	2
11	Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4. International Journal of COPD, 2018, Volume 14, 27-37.	0.9	4
12	Effect of background long-acting beta₂-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD. International Journal of COPD, 2018, Volume 13, 2917-2929.	0.9	7